AptaBio Therapeutics Inc (293780) — Cash Flow-to-Debt Ratio
AptaBio Therapeutics Inc (293780) has a Cash Flow-to-Debt Ratio of -0.12x as of September 2025, meaning its operating cash flow of ₩-2.73 Billion could theoretically repay 0% of its total liabilities (₩22.51 Billion) in one year. See how liquid is AptaBio Therapeutics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
AptaBio Therapeutics Inc Cash Flow-to-Debt Ratio (2017–2024)
Historical debt coverage capacity for AptaBio Therapeutics Inc across 8 annual periods. Also explore 293780 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for AptaBio Therapeutics Inc (2017–2024)
Year-by-year debt coverage analysis for AptaBio Therapeutics Inc. For market capitalisation and broader financial context, see AptaBio Therapeutics Inc stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.52x | ₩-12.16 Billion | ₩23.24 Billion | ▼ -15.7% |
| 2023 | -0.45x | ₩-14.10 Billion | ₩31.16 Billion | ▲ +75.2% |
| 2022 | -1.82x | ₩-6.83 Billion | ₩3.74 Billion | ▲ +33.4% |
| 2021 | -2.74x | ₩-8.90 Billion | ₩3.25 Billion | ▼ -146.5% |
| 2020 | -1.11x | ₩-3.79 Billion | ₩3.40 Billion | ▲ +58.3% |
| 2019 | -2.67x | ₩-6.00 Billion | ₩2.25 Billion | ▼ -207.8% |
| 2018 | -0.87x | ₩-1.75 Billion | ₩2.02 Billion | ▼ -1960.0% |
| 2017 | -0.04x | ₩-1.79 Billion | ₩42.54 Billion | — |